Literature DB >> 27273018

Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.

Gaetano Bertino1, Graziella Privitera2, Francesco Purrello2, Shirin Demma1, Emanuele Crisafulli1, Luisa Spadaro2, Nikolaos Koukias3, Emmanuel A Tsochatzis4.   

Abstract

Liver cirrhosis is a major cause of morbidity and mortality worldwide, mainly due to complications of portal hypertension. In this article, we review the current understanding on the pathophysiology, the diagnostic criteria and the available therapeutic options for patients with emerging hepatic syndromes in cirrhosis, namely the hepatorenal, hepato-adrenal and hepatopulmonary syndrome. The hepatorenal syndrome is a well-recognized complication of advanced cirrhosis and is usually associated with an accelerated course to death unless liver transplantation is performed. The hepatopulmonary syndrome is often missed in the evaluation of patients with cirrhosis; however, early recognition is essential for the efficient management of individual patients. The hepato-adrenal syndrome, although not fully characterized, offers an exciting field for research and potential therapeutic interventions.

Entities:  

Keywords:  Cirrhosis; Hepato-adrenal; Hepatopulmonary; Hepatorenal

Mesh:

Substances:

Year:  2016        PMID: 27273018     DOI: 10.1007/s11739-016-1478-7

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  79 in total

Review 1.  Corticosteroid insufficiency in acutely ill patients.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

2.  Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease.

Authors:  Terrence Tan; Linus Chang; Aidan Woodward; Brett McWhinney; John Galligan; Graeme A Macdonald; Jeremy Cohen; Bala Venkatesh
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

Review 3.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

4.  Assessment of adrenal function in cirrhotic patients using concentration of serum-free and salivary cortisol.

Authors:  Thierry Thevenot; Sophie Borot; Agnès Remy-Martin; Remy Sapin; Jean-Paul Cervoni; Carine Richou; Claire Vanlemmens; Denis Cleau; Emilie Muel; Anne Minello; Simona Tirziu; Alfred Penfornis; Vincent Di Martino; Elisabeth Monnet
Journal:  Liver Int       Date:  2011-01-13       Impact factor: 5.828

5.  Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

Authors:  Richard Moreau; Francois Durand; Thierry Poynard; Christian Duhamel; Jean-Paul Cervoni; Philippe Ichaï; Armand Abergel; Chantal Halimi; Mathieu Pauwels; Jean-Pierre Bronowicki; Emile Giostra; Cathy Fleurot; Danielle Gurnot; Olivier Nouel; Philippe Renard; Michel Rivoal; Pierre Blanc; Dimitri Coumaros; Sylvie Ducloux; Stephane Levy; Alexandre Pariente; Jean-Marc Perarnau; Jean Roche; Myriam Scribe-Outtas; Dominique Valla; Brigitte Bernard; Didier Samuel; Joël Butel; Antoine Hadengue; Andrzej Platek; Didier Lebrec; Jean-Francois Cadranel
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

6.  TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.

Authors:  Martin Rössle; Alexander L Gerbes
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

7.  Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome.

Authors:  Miguel R Arguedas; Britt B Drake; Ashwani Kapoor; Michael B Fallon
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

8.  Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.

Authors:  Marta Cavallin; Salvatore Piano; Antonietta Romano; Silvano Fasolato; Anna Chiara Frigo; Gianpiero Benetti; Elisabetta Gola; Filippo Morando; Marialuisa Stanco; Silvia Rosi; Antonietta Sticca; Umberto Cillo; Paolo Angeli
Journal:  Hepatology       Date:  2016-02-03       Impact factor: 17.425

9.  Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.

Authors:  R P Mookerjee; S Sen; N A Davies; S J Hodges; R Williams; R Jalan
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

10.  Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1.

Authors:  Tatyana G Vishnyakova; Alexander V Bocharov; Irina N Baranova; Zhigang Chen; Alan T Remaley; Gyorgy Csako; Thomas L Eggerman; Amy P Patterson
Journal:  J Biol Chem       Date:  2003-03-21       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.